Health Care Dysfunction Makes It to the Presidential Debate
A damning compendium of what ails the US health care industry.
Read more...Search Results for: label/Legal
Do Fewer Settlements by Pharmaceutical Companies Mean Even Less Accountability for Their Execs?
Drug company settlements with the Feds, which never were very tough to begin with, are also becoming less frequent.
Read more...What the US “Health Care Reform” Debate Did Not Address
A sobering compendium of the factors responsible for the rot in the US health care system.
Read more...As US Attorney, Trump Labor Secretary Nominee Enabled Drug and Biotechnology Executives’ Impunity
Yet another Trump appointee who was soft on big business misconduct.
Read more...Round Up No Suspects: The Bio Telemetry Settlement Demonstrates the Continuing Impunity of Health Care Organizational (and Other) Leaders
As has become usual in enforcement of laws regarding kickbacks, bribes, fraud etc, the case was resolved by a relatively small fine
Read more...How Executives Can Personally Profit from Bad Corporate Behavior in Health Care
Two Johnson & Johnson executives were prosecuted in a health care case for illegal marketing but their superiors got off scot free.
Read more...The Real Dark Side of Health Care: Health Care Corruption
A top journal excoriated two doctors who engaged in disrespectful behavior, but is vastly less vigilant or heated when faced with health care corruption, as in the sort of conduct that can and often does kill people.
Read more...How Medical “Misbranding” Puts Patients at Risk
How the anodyne term “misbranding” covers conduct which can, and too often does, lead to higher patient death rates.
Read more...Who Benefits? – Rising Generic Drug Prices and the Case of Mylan’s Conflicted Property Purchases
It’s remarkable to see the level of obvious self-dealing at Mylan persist as long as it has. Be sure to read about how the former CEO was permitted to let his son use the company jet on behalf of his rock band.
Read more...Guest Post: Predatory Pharma – An End to Too Big to Nail?
By a retired physician who worked several years in the medical communications and pharmaceutical industry who writes as Francois T Is the federal government really ready to punish those responsible of corporate malfeasance in the pharmaceutical industry? Push hard enough and you are bound to get a push back, even from a slow, at times […]
Read more...